Is the Vivelle® (ethinyl estradiol/norelgestromin) patch a synthetic hormone preparation or a bioidentical one?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vivelle Patch: Bioidentical Estrogen

The Vivelle® patch contains 17β-estradiol, which is bioidentical—structurally identical to the estrogen naturally produced by human ovaries—not synthetic. 1

Understanding the Distinction

Bioidentical vs. Synthetic Hormones

  • 17β-estradiol (the active ingredient in Vivelle) is a bioidentical hormone because it is chemically and structurally identical to the estradiol produced by the human body, even though it is synthesized from plant sources (typically soy or yam) in pharmaceutical manufacturing. 1

  • Synthetic estrogens include compounds like ethinyl estradiol (found in birth control pills and the Evra/Xulane patch) or conjugated equine estrogens (Premarin), which have different chemical structures from human hormones. 2, 3

  • The term "bioidentical" refers to molecular structure, not the source—both FDA-approved bioidentical hormones and compounded versions are laboratory-synthesized, but bioidentical hormones match human hormones exactly at the molecular level. 1

Clinical Implications of Bioidentical Estradiol

Why 17β-estradiol is preferred over synthetic estrogens:

  • Transdermal 17β-estradiol (like Vivelle) is the first-line choice for hormone replacement therapy because it bypasses hepatic first-pass metabolism, resulting in lower stroke risk (no increase vs. 28–39% increase with oral estrogen) and no elevation in venous thromboembolism risk (vs. 2–4-fold increase with oral estrogen). 2

  • The European Society of Human Reproduction and Embryology explicitly recommends 17β-estradiol over conjugated equine estrogens or ethinyl estradiol for menopausal hormone therapy due to its superior cardiovascular and thrombotic safety profile. 2

  • Bioidentical estradiol provides more physiologic hormone levels with less fluctuation compared to oral synthetic estrogens, which cause peaks and troughs in serum concentrations. 4, 5

Important Clarification: Vivelle vs. Evra/Xulane

Do not confuse Vivelle (estradiol patch for menopause) with Evra/Xulane (contraceptive patch):

  • Vivelle contains bioidentical 17β-estradiol for menopausal symptom management. 2

  • Evra/Xulane contains synthetic ethinyl estradiol plus norelgestromin (a synthetic progestin) for contraception—these are NOT bioidentical hormones. 3, 6, 4

  • The contraceptive patch delivers synthetic hormones that are structurally different from endogenous human hormones and carry higher thrombotic risks (1.6 times higher estrogen exposure than low-dose oral contraceptives). 7, 6

Evidence Quality Note

  • The classification of 17β-estradiol as bioidentical is based on established pharmaceutical chemistry and is supported by multiple guideline societies that distinguish between bioidentical and synthetic hormone formulations when making treatment recommendations. 2, 1

  • FDA-approved bioidentical estradiol products (including Vivelle) have undergone rigorous safety and efficacy testing, unlike custom-compounded bioidentical hormones, which lack standardized quality control and are not recommended by major guideline societies. 2, 1

References

Research

Bioidentical hormones for menopausal therapy.

Women's health (London, England), 2008

Guideline

Hormone Replacement Therapy Initiation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The transdermal contraceptive system.

American journal of obstetrics and gynecology, 2004

Guideline

Screening and Contraindications for the Evra Patch

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How is the CombiPatch (estradiol/norelgestromin transdermal patch) applied and how often should it be changed?
How often should the Climara (ethinyl estradiol/norelgestromin) transdermal contraceptive patch be changed?
What are the benefits of Xulane (ethinyl estradiol and norelgestromin) versus Twirla (ethinyl estradiol and levonorgestrel)?
Should I remove a contraceptive transdermal patch if there is bleeding at the application site?
Is the norelgestromin/ethinyl estradiol transdermal contraceptive patch (150 µg norelgestromin/35 µg ethinyl estradiol per day) appropriate for a healthy, non‑smoking woman under 35, and what are its contraindications, common side‑effects, and alternative contraceptive options?
In a patient with confirmed or suspected parainfluenza infection, what isolation precautions (standard, droplet, contact, airborne) are required and how long should the patient remain isolated or avoid public places/mask use?
For an 80‑plus male hospice patient with 7–8 daily voids, negative urinalysis and no bacteriuria, is initiating tamsulosin (Flomax) at bedtime plus phenazopyridine three times daily for two days appropriate, or are other treatment options recommended?
Can a pregnant woman safely use boric acid suppositories to treat vulvovaginal candidiasis?
Is a blood pressure of 90/60 mm Hg normal in a healthy 9‑year‑old child and what management is recommended?
In an asymptomatic patient with an isolated flat or inverted T wave in a single lead group on ECG, does this require modification of peri‑operative anesthetic management?
What is the clinical significance of a low eosinophil count (eosinopenia) in an asymptomatic patient without steroid use or infection, and how should it be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.